ArticleBlood advances2025

Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era.

Lianna J Marks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.